Liraglutide could reduce monthly migraine days
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat diabetes, appears to reduce monthly migraine days by more than half, researchers reported on June 20, 2025 at… read more.
A new study from Emory University addresses the growing global crisis of antibiotic-resistant infections. Many of these drug-resistant bacteria are spread through hospitals, and there are few antibiotics… read more.
Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a… read more.
Certain medications used in the treatment of bone conditions, particularly when combined with corticosteroids, may significantly increase the risk of a rare but serious jaw disease. This finding… read more.
Statin therapy reduces the risk of death significantly for patients with sepsis, researchers reported on June 6, 2025 in Frontiers in Immunology. As background, the authors noted that… read more.
Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their… read more.
Purdue University’s College of Pharmacy is now home to the Center for Research Innovation in Biotechnology and the Clinical Drug Experience Knowledgebase, a comprehensive database of every active… read more.
Among patients with ongoing, uncontrolled hypertension in spite of treatment with indapamide, amlodipine, or olmesartan, the addition of a single dose of investigative zilebesiran has, at 3 months,… read more.
In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be… read more.
Antidepressants that suppress REM (rapid eye movement) sleep appear to improve survival in people with amyotrophic lateral sclerosis (ALS). Researchers reported the finding on May 21, 2025 at… read more.
AbbVie announced the FDA has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the European Commission… read more.
April was a bumper month for drug approvals in Europe, with sixteen new products recommended by the European Medicines Agency’s (EMA) key committee on human medicines. This almost… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.